Medexus Pharmaceuticals Inc.
MDP
Rank in Stocks
#19024
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and... Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The companyโs products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.
Share Price
$3.70
Last synced: 2026-11-09
Market Cap
$116.39M
Change (1 day)
2.15%
Change (1 year)
93.74%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Medexus Pharmaceuticals Inc. (MDP)
Category
Healthcare
Operating Margin for Medexus Pharmaceuticals Inc. (MDP)
Operating Margin as of November 2026 TTM: 6.64%
According to Medexus Pharmaceuticals Inc.'s latest financial reports, its current operating margin (TTM) is 6.64%. At the end of 2025 the company had an operating margin of 7.59%.
Operating Margin history for Medexus Pharmaceuticals Inc. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 6.64% | -12.52% |
| 2025 | 7.59% | -20.52% |
| 2024 | 9.55% | 35.65% |
| 2023 | 7.04% | -136.01% |
| 2022 | -19.55% | 1,030.06% |
| 2021 | -1.73% | -84.33% |
| 2020 | -11.04% | -33.97% |
| 2019 | -16.72% | -40.98% |
| 2018 | -28.33% | 122.72% |
| 2017 | -12.72% | -64.39% |
| 2016 | -35.72% | -78.29% |
| 2015 | -164.51% | 3.41% |
| 2014 | -159.09% | 2,564.82% |
| 2013 | -5.97% | 0.00% |
| 2012 | -5.97% | 0.00% |
| 2011 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 62.34% | -90.61% |
US
|
|
| 31.60% | -95.24% |
SE
|
|
| 30.13% | -95.46% |
FR
|
|
| 29.76% | -95.52% |
HK
|
|
| 30.46% | -95.41% |
IT
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Medexus Pharmaceuticals Inc.'s operating margin
What is Medexus Pharmaceuticals Inc.'s operating margin?
Medexus Pharmaceuticals Inc.'s operating margin is 6.64%, as of Nov 2026.
What was Medexus Pharmaceuticals Inc.'s operating margin in 2025?
In 2025, Medexus Pharmaceuticals Inc.'s operating margin was 7.59%, compared with 9.55% in 2024.
How has Medexus Pharmaceuticals Inc.'s operating margin changed since 2020?
From 2020 to 2025, Medexus Pharmaceuticals Inc.'s operating margin was highest in 2024 (9.55%) and lowest in 2022 (-19.55%).
How does Medexus Pharmaceuticals Inc.'s operating margin compare with similar companies?
Medexus Pharmaceuticals Inc.'s operating margin (6.64%) is lower than that of all 5 similar companies listed above. The highest among them is Royalty Pharma plc, with 62.34%.